Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide.

Rodrigueza WV, Woolliscroft MJ, Ebrahim AS, Forgey R, McGovren PJ, Endert G, Wagner A, Holewa D, Aboukameel A, Gill RD, Bisgaier CL, Messmann RA, Whitehead CE, Izbicka E, Streeper R, Wick MC, Stiegler G, Stein CA, Monsma D, Webb C, Sooch MP, Panzner S, Mohammad R, Goodwin NC, Al-Katib A.

Cancer Chemother Pharmacol. 2014 Jul;74(1):151-66. doi: 10.1007/s00280-014-2476-y. Epub 2014 May 16.

2.

Plasma biomarkers distinguish non-small cell lung cancer from asthma and differ in men and women.

Izbicka E, Streeper RT, Michalek JE, Louden CL, Diaz A 3rd, Campos DR.

Cancer Genomics Proteomics. 2012 Jan;9(1):27-35.

PMID:
22210046
3.

Effects of alpha-difluoromethylornithine on markers of proliferation, invasion, and apoptosis in breast cancer.

Izbicka E, Streeper RT, Yeh IT, Pressley O, Grant M, Andrews JV, Kuhn J, O'Shaughnessy J.

Anticancer Res. 2010 Jun;30(6):2263-9.

PMID:
20651378
4.

Quantitative analysis of the effect of tubulin isotype expression on sensitivity of cancer cell lines to a set of novel colchicine derivatives.

Tseng CY, Mane JY, Winter P, Johnson L, Huzil T, Izbicka E, Luduena RF, Tuszynski JA.

Mol Cancer. 2010 May 30;9:131. doi: 10.1186/1476-4598-9-131.

5.

Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers.

Izbicka E, Diaz A, Streeper R, Wick M, Campos D, Steffen R, Saunders M.

Cancer Chemother Pharmacol. 2009 Oct;64(5):993-9. doi: 10.1007/s00280-009-0954-4. Epub 2009 Feb 17.

6.

Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.

McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH, Chan DW, Diaz J, Izbicka E, Kagan J, Malehorn DE, Malik G, Oelschlager D, Partin A, Randolph T, Rosenzweig N, Srivastava S, Srivastava S, Thompson IM, Thornquist M, Troyer D, Yasui Y, Zhang Z, Zhu L, Semmes OJ.

Clin Chem. 2008 Jan;54(1):44-52. Epub 2007 Nov 2.

7.

Regulation of tumor signaling pathways by AZD3409 in vitro.

Streeper R, Campos D, Carrizales G, Stephens TC, Izbicka E.

Anticancer Res. 2006 Nov-Dec;26(6B):4185-9.

8.

Prognostic significance of biochemical heterogeneity of catecholaminergic clones in neuroblastoma.

Izbicki T, Izbicka E, Mazur J.

J Pediatr Surg. 2006 Sep;41(9):1506-12.

PMID:
16952582
9.

Molecular determinants of differential sensitivity to docetaxel and paclitaxel in human pediatric cancer models.

Izbicka E, Campos D, Marty J, Carrizales G, Mangold G, Tolcher A.

Anticancer Res. 2006 May-Jun;26(3A):1983-8.

10.

A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.

Mita MM, Rowinsky EK, Forero L, Eckhart SG, Izbicka E, Weiss GR, Beeram M, Mita AC, de Bono JS, Tolcher AW, Hammond LA, Simmons P, Berg K, Takimoto C, Patnaik A.

Cancer Chemother Pharmacol. 2007 Feb;59(2):165-74. Epub 2006 May 31.

PMID:
16736151
11.

Therapeutic strategies for the treatment of neuroblastoma.

Izbicka E, Izbicki T.

Curr Opin Investig Drugs. 2005 Dec;6(12):1200-14. Review.

PMID:
16370386
12.

A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.

Mita MM, Ochoa L, Rowinsky EK, Kuhn J, Schwartz G, Hammond LA, Patnaik A, Yeh IT, Izbicka E, Berg K, Tolcher AW.

Ann Oncol. 2006 Feb;17(2):313-21. Epub 2005 Dec 1.

PMID:
16322117
13.

Biomarkers of anticancer activity of R115777 (Tipifarnib, Zarnestra) in human breast cancer models in vitro.

Izbicka E, Campos D, Carrizales G, Patnaik A.

Anticancer Res. 2005 Sep-Oct;25(5):3215-23.

14.

A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer.

Tolcher AW, Chi K, Kuhn J, Gleave M, Patnaik A, Takimoto C, Schwartz G, Thompson I, Berg K, D'Aloisio S, Murray N, Frankel SR, Izbicka E, Rowinsky E.

Clin Cancer Res. 2005 May 15;11(10):3854-61.

15.

Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility.

Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Srivastava S, Thompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L.

Clin Chem. 2005 Jan;51(1):102-12.

16.
17.

Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony-forming units, and xenografts.

van Laar ES, Izbicka E, Weitman S, Medina-Gundrum L, Macdonald JR, Waters SJ.

Int J Gynecol Cancer. 2004 Sep-Oct;14(5):824-31.

PMID:
15361190
18.

A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.

Tolcher AW, Kuhn J, Schwartz G, Patnaik A, Hammond LA, Thompson I, Fingert H, Bushnell D, Malik S, Kreisberg J, Izbicka E, Smetzer L, Rowinsky EK.

Clin Cancer Res. 2004 Aug 1;10(15):5048-57.

19.

The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology.

Grizzle WE, Semmes OJ, Basler J, Izbicka E, Feng Z, Kagan J, Adam BL, Troyer D, Srivastava S, Thornquist M, Zhang Z, Thompson IM.

Urol Oncol. 2004 Jul-Aug;22(4):337-43. Review.

PMID:
15283893
20.

Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer.

Grizzle WE, Adam BL, Bigbee WL, Conrads TP, Carroll C, Feng Z, Izbicka E, Jendoubi M, Johnsey D, Kagan J, Leach RJ, McCarthy DB, Semmes OJ, Srivastava S, Srivastava S, Thompson IM, Thornquist MD, Verma M, Zhang Z, Zou Z.

Dis Markers. 2003-2004;19(4-5):185-95.

21.

Development of novel alkylating drugs as anticancer agents.

Izbicka E, Tolcher AW.

Curr Opin Investig Drugs. 2004 Jun;5(6):587-91. Review.

PMID:
15242245
23.

Elimination of extrachromosomal c-myc genes by hydroxyurea induces apoptosis.

Petit T, Davidson K, Izbicka E, Von Hoff DD.

Apoptosis. 1999 Jun;4(3):163-7.

PMID:
14634278
24.

A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.

Patnaik A, Eckhardt SG, Izbicka E, Tolcher AA, Hammond LA, Takimoto CH, Schwartz G, McCreery H, Goetz A, Mori M, Terada K, Gentner L, Rybak ME, Richards H, Zhang S, Rowinsky EK.

Clin Cancer Res. 2003 Oct 15;9(13):4761-71.

25.

Varicella zoster virus infections in neuroblastoma patients: a 31-year clinical study.

Izbicki T, Mazur J, Izbicka E.

Anticancer Res. 2003 May-Jun;23(3C):3061-8.

PMID:
12926162
26.

Epidemiology of neuroblastoma: analysis of a single institution.

Izbicki T, Mazur J, Izbicka E.

Anticancer Res. 2003 Mar-Apr;23(2C):1933-8.

PMID:
12820482
27.
28.

The use of early sea urchin embryos in anticancer drug testing.

Nishioka D, Marcell V, Cunningham M, Khan M, Von Hoff DD, Izbicka E.

Methods Mol Med. 2003;85:265-76. Review. No abstract available.

PMID:
12710214
29.

Epidemiology and etiology of neuroblastoma: an overview.

Izbicki T, Mazur J, Izbicka E.

Anticancer Res. 2003 Jan-Feb;23(1B):755-60. Review.

PMID:
12680179
30.

Design and synthesis of fluoroquinophenoxazines that interact with human telomeric G-quadruplexes and their biological effects.

Duan W, Rangan A, Vankayalapati H, Kim MY, Zeng Q, Sun D, Han H, Fedoroff OY, Nishioka D, Rha SY, Izbicka E, Von Hoff DD, Hurley LH.

Mol Cancer Ther. 2001 Dec;1(2):103-20.

31.

Efficient induction of apoptosis by ONYX-015 adenovirus in human colon cancer cell lines regardless of p53 status.

Petit T, Davidson KK, Cerna C, Lawrence RA, Von Hoff DD, Heise C, Kirn D, Izbicka E.

Anticancer Drugs. 2002 Jan;13(1):47-50.

PMID:
11914640
32.

The synthesis and screening of 1,4,5,8-naphthalenetetracarboxylic diimide-peptide conjugates with antibacterial activity.

Miller CT, Weragoda R, Izbicka E, Iverson BL.

Bioorg Med Chem. 2001 Aug;9(8):2015-24.

PMID:
11504638
33.

Alterations in DNA repair and telomere maintenance mechanism affect response to porphyrins in yeast.

Izbicka E, Barnes LD, Robinson AK, Davidson KK, Lawrence RA, Hannibal GT.

Anticancer Res. 2001 May-Jun;21(3B):1899-903.

PMID:
11497275
34.

Exploring the mechanisms of action of FB642 at the cellular level.

Hammond LA, Davidson K, Lawrence R, Camden JB, Von Hoff DD, Weitman S, Izbicka E.

J Cancer Res Clin Oncol. 2001 May;127(5):301-13.

PMID:
11355145
35.

Effects of hydroxyurea on extrachromosomal DNA in patients with advanced ovarian carcinomas.

Raymond E, Faivre S, Weiss G, McGill J, Davidson K, Izbicka E, Kuhn JG, Allred C, Clark GM, Von Hoff DD.

Clin Cancer Res. 2001 May;7(5):1171-80.

36.

Neuropeptide receptor status in human tumor cell lines.

Petit T, Davidson KK, Lawrence RA, von Hoff DD, Izbicka E.

Anticancer Drugs. 2001 Feb;12(2):133-6.

PMID:
11261886
37.

Tetracationic porphyrins inhibit angiogenesis induced by human tumor cells in vivo.

Izbicka E, Sommer E, Skopinska-Rozewska E, Davidson K, Wu RS, Orlowski T, Pastewka K.

Anticancer Res. 2000 Sep-Oct;20(5A):3205-10.

PMID:
11062744
38.

DNA G-quadruplexes, telomere-specific proteins and telomere-associated enzymes as potential targets for new anticancer drugs.

Raymond E, Soria JC, Izbicka E, Boussin F, Hurley L, Von Hoff DD.

Invest New Drugs. 2000 May;18(2):123-37. Review.

PMID:
10857992
39.

A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors.

Tolcher AW, Aylesworth C, Rizzo J, Izbicka E, Campbell E, Kuhn J, Weiss G, Von Hoff DD, Rowinsky EK.

Ann Oncol. 2000 Mar;11(3):333-8.

PMID:
10811501
40.

Effects of androgens on telomerase activity in normal and malignant prostate cells in vitro.

Soda H, Raymond E, Sharma S, Lawrence R, Davidson K, Oka M, Kohno S, Izbicka E, Von Hoff DD.

Prostate. 2000 May 15;43(3):161-8.

PMID:
10797490
41.

Effect of telomere and telomerase interactive agents on human tumor and normal cell lines.

Rha SY, Izbicka E, Lawrence R, Davidson K, Sun D, Moyer MP, Roodman GD, Hurley L, Von Hoff D.

Clin Cancer Res. 2000 Mar;6(3):987-93.

42.

G-quadruplexes as targets for drug design.

Hurley LH, Wheelhouse RT, Sun D, Kerwin SM, Salazar M, Fedoroff OY, Han FX, Han H, Izbicka E, Von Hoff DD.

Pharmacol Ther. 2000 Mar;85(3):141-58. Review.

PMID:
10739869
43.

Telomere-interactive agents affect proliferation rates and induce chromosomal destabilization in sea urchin embryos.

Izbicka E, Nishioka D, Marcell V, Raymond E, Davidson KK, Lawrence RA, Wheelhouse RT, Hurley LH, Wu RS, Von Hoff DD.

Anticancer Drug Des. 1999 Aug;14(4):355-65.

PMID:
10625928
44.

Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units.

Hidalgo M, Izbicka E, Eckhardt SG, MacDonald JR, Cerna C, Gomez L, Rowinsky EK, Weitman SD, Von Hoff DD.

Anticancer Drugs. 1999 Oct;10(9):837-44.

PMID:
10587294
45.

Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells.

Lawrence RA, Izbicka E, De Jager RL, Tohgo A, Clark GM, Weitman SD, Rowinsky EK, Von Hoff DD.

Anticancer Drugs. 1999 Aug;10(7):655-61.

PMID:
10507315
46.

A human breast cancer model for the study of telomerase inhibitors based on a new biotinylated-primer extension assay.

Raymond E, Sun D, Izbicka E, Mangold G, Silvas E, Windle B, Sharma S, Soda H, Laurence R, Davidson K, Von Hoff DD.

Br J Cancer. 1999 Jul;80(9):1332-41.

47.

Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay.

Britten CD, Izbicka E, Hilsenbeck S, Lawrence R, Davidson K, Cerna C, Gomez L, Rowinsky EK, Weitman S, Von Hoff DD.

Cancer Chemother Pharmacol. 1999;44(2):105-10.

PMID:
10412943
48.

Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units.

Petit T, Izbicka E, Lawrence RA, Bishop WR, Weitman S, Von Hoff DD.

Ann Oncol. 1999 Apr;10(4):449-53.

PMID:
10370788
49.

Cytotoxic effects of MGI 114 are independent of tumor p53 or p21 expression.

Izbicka E, Davidson K, Lawrence R, Cote R, MacDonald JR, Von Hoff DD.

Anticancer Res. 1999 Mar-Apr;19(2A):1299-307.

PMID:
10368691
50.

5,6-Dihydro-5'-azacytidine (DHAC) affects estrogen sensitivity in estrogen-refractory human breast carcinoma cell lines.

Izbicka E, Davidson KK, Lawrence RA, MacDonald JR, Von Hoff DD.

Anticancer Res. 1999 Mar-Apr;19(2A):1293-8.

PMID:
10368690

Supplemental Content

Loading ...
Support Center